Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
Dr. Denise Scots-Knight is the Chief Executive Officer of Mereo BioPharma Group PLC, joining the firm since 2015.
What is the price performance of MREO stock?
The current price of MREO is $0.3265, it has increased 3.25% in the last trading day.
What are the primary business themes or industries for Mereo BioPharma Group PLC?
Mereo BioPharma Group PLC belongs to Biotechnology industry and the sector is Health Care
What is Mereo BioPharma Group PLC market cap?
Mereo BioPharma Group PLC's current market cap is $51.9M
Is Mereo BioPharma Group PLC a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Mereo BioPharma Group PLC, including 7 strong buy, 7 buy, 1 hold, 0 sell, and 7 strong sell